Faeth Therapeutics
FTH
45 hedge funds and large institutions have $334M invested in Faeth Therapeutics in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 2 reducing their positions, and 7 closing their positions.
1,796% more capital inflows, than outflows
Capital inflows: $287M | Capital outflows: $15.1M
750% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 2
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
50% more funds holding
Funds holding: 30 → 45 (+15)
116.51% less ownership
Funds ownership: 170.97% → 54.46% (-117%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
+$45.9M |
| 2 |
Avoro Capital Advisors
New York
|
+$33.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$29.8M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$23.7M |
| 5 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.62M |
| 2 |
Stempoint Capital
New York
|
-$4.19M |
| 3 |
Goldman Sachs
New York
|
-$1.94M |
| 4 |
HRT Financial
New York
|
-$1.83M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.04M |
FTH Hedge Fund Activity: Q2 2026 in Review
45 of the 8,364 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2026, worth a combined $334M — up 391% from $68M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FTH positions and 7 closed out — a net gain of 15 holders — while 17 added to existing stakes and 2 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $45.9M. The largest seller was Millennium Management, exiting entirely with an estimated $4.62M sold.
- 45 institutional investors held Faeth Therapeutics (FTH) as of Q2 2026, up from 30 in Q1 2026.
- Funds reported $334M of Faeth Therapeutics stock for Q2 2026, up 391% quarter-over-quarter.
- 22 funds opened new Faeth Therapeutics positions in Q2 2026 and 7 closed out, a net change of +15 holders.
- The largest Faeth Therapeutics buyer in Q2 2026 was Suvretta Capital Management, an estimated $45.9M added.
- The largest Faeth Therapeutics seller in Q2 2026 was Millennium Management, an estimated $4.62M sold.
Based on aggregated 13F filings for Q2 2026.